{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T10:47:26Z","timestamp":1788432446079,"version":"build-2803163510"},"reference-count":49,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Tamsulosin is the most common treatment for lower urinary tract symptoms (LUTS) attributed to benign prostatic hyperplasia (BPH). The ability of N-of-1 deprescribing trials to identify who may benefit from discontinuing chronic tamsulosin therapy is unknown.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To determine if N-of-1 deprescribing trials can identify older men who are receiving minimal benefit from tamsulosin therapy for LUTS.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n Double-blind, placebo-controlled, multiple crossover (N-of-1) randomized clinical trial conducted at a single academic urology department between September 2021 and July 2022. After a 1-week placebo run-in, men aged 55 to 80 years who were continuous users of tamsulosin for at least 12 months to treat symptoms of BPH were randomly assigned to 2 blocks of 2-week treatment periods alternating tamsulosin and placebo, separated by 1-week washout periods. Data were analyzed from November 2022 to October 2024.<\/jats:p>\n <\/jats:sec>\n \n Intervention<\/jats:title>\n Tamsulosin, dosed at either 0.4 mg or 0.8 mg, vs matching placebo.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomess and Measures<\/jats:title>\n The efficacy outcome was daily American Urological Association Symptom Index (AUASI) with an adapted recall period of 24 hours. Effect size was categorized based on the upper bound of the individual 95% CI for the tamsulosin-placebo difference in daily AUASI: minimal or no (\u22650), moderate (&amp;gt;\u22126.0 to &amp;lt;0), or strong (\u2264\u22126.0) effect. Adverse drug events were assessed daily as a secondary outcome. Demographics, clinical characteristics, and attitudes toward deprescribing were assessed at baseline.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Among the 31 participants enrolled, the mean (SD) age was 68.8 (5.7) years. Of 30 participants who attempted the full N-of-1 protocol, 11 (36.7%) had minimal or no tamsulosin effect, 11 (36.7%) had moderate effect, 4 (13.3%) had strong effect, and 4 (13.3%) did not tolerate the 1-week placebo run-in due to worsening symptoms. Based on a mean (SD) of 54 (3) daily LUTS assessments per participant, individual-level estimated mean difference in daily AUASI between tamsulosin and placebo ranged from \u221210.9 (95% CI, \u221212.6 to \u22129.1) to 2.1 (95% CI, 0.4 to 3.9). The group-level mean difference in daily AUASI was \u22122.96 (95% CI, \u22124.37 to \u22121.54).<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this randomized N-of-1 clinical trial of tamsulosin deprescribing, treatment response was heterogeneous. The findings suggest that 1 in 3 older men who had minimal symptomatic benefit from tamsulosin may be high-priority candidates for deprescribing.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT05415748<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.21639","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T15:06:31Z","timestamp":1783350391000},"page":"e2621639","source":"Crossref","is-referenced-by-count":1,"title":["Tamsulosin Deprescribing for Lower Urinary Tract Symptoms in Older Men"],"prefix":"10.1001","volume":"9","author":[{"given":"Scott R.","family":"Bauer","sequence":"first","affiliation":[{"name":"Division of General Internal Medicine, Department of Medicine, University of California, San Francisco"},{"name":"Department of Urology, University of California, San Francisco"},{"name":"San Francisco VA Healthcare System, San Francisco, California"},{"name":"Department of Epidemiology and Biostatistics, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey A.","family":"Kenfield","sequence":"additional","affiliation":[{"name":"Department of Urology, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinyemi","family":"Oni-Orisan","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Shlipak","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine, Department of Medicine, University of California, San Francisco"},{"name":"San Francisco VA Healthcare System, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiwei","family":"Lu","sequence":"additional","affiliation":[{"name":"San Francisco VA Healthcare System, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Rios","sequence":"additional","affiliation":[{"name":"Department of Urology, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Pearce","sequence":"additional","affiliation":[{"name":"Department of Urology, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Harmon","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles E.","family":"McCulloch","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liusheng","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Steinman","sequence":"additional","affiliation":[{"name":"Division of Geriatrics, Department of Medicine, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin N.","family":"Breyer","sequence":"additional","affiliation":[{"name":"Department of Urology, University of California, San Francisco"},{"name":"Department of Epidemiology and Biostatistics, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"issue":"5","key":"zoi260601r1","doi-asserted-by":"publisher","first-page":"S75","DOI":"10.1016\/j.juro.2008.03.141","article-title":"Urologic diseases in america project: benign prostatic hyperplasia.","volume":"179","author":"Wei","year":"2008","journal-title":"J Urol"},{"issue":"6","key":"zoi260601r2","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S0090-4295(94)80165-7","article-title":"Natural history of prostatism: impact of urinary symptoms on quality of life in 2115 randomly selected community men.","volume":"44","author":"Girman","year":"1994","journal-title":"Urology"},{"issue":"3","key":"zoi260601r3","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0090-4295(97)00717-6","article-title":"Health-related quality of life associated with lower urinary tract symptoms in four countries.","volume":"51","author":"Girman","year":"1998","journal-title":"Urology"},{"issue":"6","key":"zoi260601r4","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/S0302-2838(02)00172-0","article-title":"Health status and its correlates among Dutch community-dwelling older men with and without lower urogenital tract dysfunction.","volume":"41","author":"Blanker","year":"2002","journal-title":"Eur Urol"},{"issue":"6","key":"zoi260601r5","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1046\/j.1464-410X.2003.04448.x","article-title":"The relationship between lower urinary tract symptoms and health status: the UREPIK study.","volume":"92","author":"Boyle","year":"2003","journal-title":"BJU Int"},{"issue":"2","key":"zoi260601r6","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0090-4295(01)01506-0","article-title":"Quality-of-life impact of lower urinary tract symptom severity: results from the Health Professionals Follow-up Study.","volume":"59","author":"Welch","year":"2002","journal-title":"Urology"},{"issue":"4","key":"zoi260601r7","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.urology.2006.04.019","article-title":"Prevalence, severity, and health correlates of lower urinary tract symptoms among older men: the MrOS study.","volume":"68","author":"Taylor","year":"2006","journal-title":"Urology"},{"issue":"4","key":"zoi260601r8","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1111\/jgs.17633","article-title":"Lower urinary tract symptoms and incident functional limitations among older community-dwelling men.","volume":"70","author":"Bauer","year":"2022","journal-title":"J Am Geriatr Soc"},{"issue":"4","key":"zoi260601r9","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1111\/jgs.17633","article-title":"Lower urinary tract symptom severity, urinary bother, and incident life-space mobility restriction among older men.","volume":"71","author":"Bauer","year":"2022","journal-title":"J Am Geriatr Soc"},{"issue":"3","key":"zoi260601r10","doi-asserted-by":"publisher","first-page":"168","DOI":"10.3109\/13685538.2016.1169399","article-title":"A systematic review of the association between lower urinary tract symptoms and falls, injuries, and fractures in community-dwelling older men.","volume":"19","author":"Noguchi","year":"2016","journal-title":"Aging Male"},{"issue":"6","key":"zoi260601r11","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1097\/JU.0000000000002450","article-title":"Lower urinary tract symptoms and mortality among Finnish men: the roles of symptom severity and bother.","volume":"207","author":"\u00c5kerla","year":"2022","journal-title":"J Urol"},{"issue":"3","key":"zoi260601r12","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1097\/JU.0000000000000463","article-title":"he impact of nocturia on mortality: a systematic review and meta-analysis.","volume":"203","author":"Pesonen","year":"2019","journal-title":"J Urol"},{"issue":"1","key":"zoi260601r13","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1097\/JU.0000000000000499","article-title":"Trends in lower urinary tract symptoms associated with benign prostatic hyperplasia, 2004 to 2013: the urologic diseases in America project.","volume":"203","author":"Welliver","year":"2020","journal-title":"J Urol"},{"issue":"6","key":"zoi260601r14","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.urology.2013.07.062","article-title":"Trends in medical management of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.","volume":"82","author":"Filson","year":"2013","journal-title":"Urology"},{"issue":"5","key":"zoi260601r15","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/S0302-2838(03)00376-2","article-title":"Treatment strategies, patterns of drug use and treatment discontinuation in men with LUTS suggestive of benign prostatic hyperplasia: the Triumph project.","volume":"44","author":"Verhamme","year":"2003","journal-title":"Eur Urol"},{"issue":"12","key":"zoi260601r16","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s11934-020-01015-9","article-title":"Medication discontinuation following transurethral prostatectomy: an unrecognized effectiveness measure?","volume":"21","author":"Campbell","year":"2020","journal-title":"Curr Urol Rep"},{"issue":"5","key":"zoi260601r17","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1093\/ageing\/afv077","article-title":"Appropriateness of oral drugs for long-term treatment of lower urinary tract symptoms in older persons: results of a systematic literature review and international consensus validation process (LUTS-FORTA 2014).","volume":"44","author":"Oelke","year":"2015","journal-title":"Age Ageing"},{"issue":"4","key":"zoi260601r18","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S0302-2838(03)00367-1","article-title":"Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride.","volume":"44","author":"Barkin","year":"2003","journal-title":"Eur Urol"},{"issue":"9","key":"zoi260601r19","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1111\/ijcp.12108","article-title":"Evaluation of patient outcome after discontinuation of alfuzosin treatment for benign prostatic hyperplasia: a multicentre, prospective study.","volume":"67","author":"Chung","year":"2013","journal-title":"Int J Clin Pract"},{"key":"zoi260601r20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-2042.2007.01784.x","article-title":"Natural course of lower urinary tract symptoms following discontinuation of alpha-1-adrenergic blockers in patients with benign prostatic hyperplasia.","author":"Yokoyama","year":"2007","journal-title":"Int J Urol"},{"issue":"2","key":"zoi260601r21","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/ageing\/afu145","article-title":"STOPP\/START criteria for potentially inappropriate prescribing in older people: version 2.","volume":"44","author":"O\u2019Mahony","year":"2015","journal-title":"Age Ageing"},{"issue":"2","key":"zoi260601r22","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.urology.2013.10.003","article-title":"Natural course of lower urinary tract symptoms in men not requiring treatment\u2013a 5-year longitudinal population-based study.","volume":"83","author":"P\u00f6yh\u00f6nen","year":"2014","journal-title":"Urology"},{"issue":"5","key":"zoi260601r24","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1016\/S0022-5347(17)36966-5","article-title":"The American Urological Association symptom index for benign prostatic hyperplasia.","volume":"148","author":"Barry","year":"1992","journal-title":"J Urol"},{"issue":"5","key":"zoi260601r25","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1016\/S0022-5347(01)66780-6","article-title":"Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?","volume":"154","author":"Barry","year":"1995","journal-title":"J Urol"},{"issue":"12","key":"zoi260601r26","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-032795","article-title":"Determining the minimal important differences in the International Prostate Symptom Score and Overactive Bladder Questionnaire: results from an observational cohort study in Dutch primary care.","volume":"9","author":"Blanker","year":"2019","journal-title":"BMJ Open"},{"issue":"5","key":"zoi260601r27","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1016\/j.juro.2011.01.074","article-title":"Update on AUA guideline on the management of benign prostatic hyperplasia.","volume":"185","author":"McVary","year":"2011","journal-title":"J Urol"},{"issue":"2","key":"zoi260601r28","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.amepre.2016.07.033","article-title":"Institute of medicine measures of social and behavioral determinants of health: a feasibility study.","volume":"52","author":"Giuse","year":"2017","journal-title":"Am J Prev Med"},{"issue":"7","key":"zoi260601r29","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1007\/s11136-018-1842-3","article-title":"PROMIS\u00ae-29 v2.0 profile physical and mental health summary scores.","volume":"27","author":"Hays","year":"2018","journal-title":"Qual Life Res"},{"issue":"12","key":"zoi260601r30","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1097\/MLR.0b013e318269e121","article-title":"Initial validation of a self-report measure of the extent of and reasons for medication nonadherence.","volume":"50","author":"Voils","year":"2012","journal-title":"Med Care"},{"issue":"10","key":"zoi260601r31","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1007\/s10620-019-05621-7","article-title":"Content validity and reliability of a self-report measure of medication nonadherence in hepatitis C treatment.","volume":"64","author":"Voils","year":"2019","journal-title":"Dig Dis Sci"},{"issue":"12","key":"zoi260601r32","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s40266-016-0410-1","article-title":"Development and validation of the revised patients\u2019 attitudes towards deprescribing (rPATD) questionnaire: versions for older adults and caregivers.","volume":"33","author":"Reeve","year":"2016","journal-title":"Drugs Aging"},{"issue":"10","key":"zoi260601r34","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1001\/jamainternmed.2018.3981","article-title":"Effect of Mobile device\u2013supported single-patient multi-crossover trials on treatment of chronic musculoskeletal pain: a randomized clinical trial.","volume":"178","author":"Kravitz","year":"2018","journal-title":"JAMA Intern Med"},{"issue":"6","key":"zoi260601r35","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s10916-016-0492-7","article-title":"Use of mobile health applications for health-seeking behavior among US adults.","volume":"40","author":"Bhuyan","year":"2016","journal-title":"J Med Syst"},{"issue":"5","key":"zoi260601r36","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1111\/j.1752-8062.2011.00347.x","article-title":"Recommendations for planning pilot studies in clinical and translational research.","volume":"4","author":"Moore","year":"2011","journal-title":"Clin Transl Sci"},{"issue":"11","key":"zoi260601r37","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/j.jclinepi.2015.04.014","article-title":"A simple formula for the calculation of sample size in pilot studies.","volume":"68","author":"Viechtbauer","year":"2015","journal-title":"J Clin Epidemiol"},{"issue":"27","key":"zoi260601r38","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000000974","article-title":"Comparative effectiveness and safety of monodrug therapies for lower urinary tract symptoms associated with benign prostatic hyperplasia: a network meta-analysis.","volume":"94","author":"Yuan","year":"2015","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"zoi260601r39","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1001\/jama.287.5.622","article-title":"Nonspecific medication side effects and the nocebo phenomenon.","volume":"287","author":"Barsky","year":"2002","journal-title":"JAMA"},{"issue":"3","key":"zoi260601r40","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.eururo.2006.05.014","article-title":"The placebo effect in the pharmacologic treatment of patients with lower urinary tract symptoms.","volume":"50","author":"van Leeuwen","year":"2006","journal-title":"Eur Urol"},{"issue":"6","key":"zoi260601r41","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1016\/j.juro.2015.06.091","article-title":"Clinically and statistically significant changes seen in sham surgery arms of randomized, controlled benign prostatic hyperplasia surgery trials.","volume":"194","author":"Welliver","year":"2015","journal-title":"J Urol"},{"issue":"2","key":"zoi260601r42","doi-asserted-by":"publisher","first-page":"e70","DOI":"10.1016\/S1470-2045(15)00396-4","article-title":"Research methods to change clinical practice for patients with rare cancers.","volume":"17","author":"Billingham","year":"2016","journal-title":"Lancet Oncol"},{"issue":"11","key":"zoi260601r43","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1212\/WNL.0000000000011597","article-title":"Systematic review of N-of-1 studies in rare genetic neurodevelopmental disorders: the power of 1.","volume":"96","author":"M\u00fcller","year":"2021","journal-title":"Neurology"},{"issue":"10","key":"zoi260601r44","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2023.103688","article-title":"Toward responsible clinical n-of-1 strategies for rare diseases.","volume":"28","author":"Defelippe","year":"2023","journal-title":"Drug Discov Today"},{"issue":"4","key":"zoi260601r45","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1001\/jamapediatrics.2020.5801","article-title":"Experimental designs to optimize treatments for individuals: personalized N-of-1 trials.","volume":"175","author":"Davidson","year":"2021","journal-title":"JAMA Pediatr"},{"issue":"10","key":"zoi260601r46","doi-asserted-by":"publisher","first-page":"4460","DOI":"10.1111\/bcp.15442","article-title":"N-of-1 trials to facilitate evidence-based deprescribing: rationale and case study.","volume":"88","author":"Goyal","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"zoi260601r47","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1093\/ageing\/31.4.227","article-title":"N-of-1 randomized controlled trials (\u2018N-of-1 trials\u2019): singularly useful in geriatric medicine.","volume":"31","author":"Price","year":"2002","journal-title":"Age Ageing"},{"issue":"4","key":"zoi260601r48","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1046\/j.1532-5415.2001.49092.x","article-title":"Toward individualized evidence-based medicine: five \u201cN of 1\u201d trials of methylphenidate in geriatric patients.","volume":"49","author":"Jansen","year":"2001","journal-title":"J Am Geriatr Soc"},{"issue":"6","key":"zoi260601r49","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.120.007793","article-title":"Unblinded and blinded N-of-1 trials versus usual care: a randomized controlled trial to increase statin uptake in primary care.","volume":"15","author":"Tudor","year":"2022","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"zoi260601r33","volume-title":"Generalized, Linear, and Mixed Models","author":"McCulloch","year":"2011"},{"key":"zoi260601r23","unstructured":"Astellas Pharma Inc. Flomax (tamsulosin hydrochloride) [package insert]. U.S. Food and Drug Administration website. Revised July 2006. Accessed November 17, 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/020579s020lbl.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2851139\/bauer_2026_oi_260601_1782493116.16857.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T15:06:43Z","timestamp":1783350403000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2851139"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":49,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.21639","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]}}}